Emi Caywood

Has grant

Director, Transplant and Cellular Therapy

Alfred I DuPont Hospital for Children
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Nemours NCI Community Oncology Research Program (NCORP)

Open Date: 2014-08-01

Close Date: 2025-07-31

Articles (10)

Year:

2026

Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biological entity. We hypothesized that there exist different biological subtypes of cGVHD. Using the Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) network database, which is derived from the largest pediatric cGVHD cohort worldwide, we applied clustering analysis to subtype patients with cGVHD from the ABLE1.0 and 2.0 studies (51 patients with cGVHD and 158 with non-cGVHD). We found 3 distinct cGVHD subtypes: cGVHD-1 was characterized by an effector memory T-cell, cytotoxic natural killer cell, and early precursor B-cell predominant pattern; cGVHD-2 was phosphatidylcholine, cytokine, and plasma cell predominant; and cGVHD-3 had more naïve CD4+ T cells and naïve regulatory T cells, had later onset, and was the only subtype with measurable T-cell receptor excision circles. We partially replicated these subtypes using metabolomic data from a separate pediatric cohort of the Children’s Oncology Group trial ASCT0031 (33 patients with cGVHD and 39 with non-cGVHD). Furthermore, cGVHD-1 was associated with serotherapy (predominantly antithymocyte globulin) exposure, and cGVHD-3 was associated with receiving peripheral blood stem cells from donors, total body irradiation, and no previous acute GVHD. cGVHD-2 was associated with liver involvement and cGVHD-2 and -3 with de novo cGVHD. Overall, none of the subtypes were closely associated with organ involvement. Contrasting each subtype against patients with non-cGVHD, the 3 subtypes shared common markers, all of which were used in our previous cGVHD diagnostic classifier. These findings suggest the presence of distinct biological subtypes of cGVHD that may help guide therapeutic strategies.

Year:

2026

PURPOSE The objective was to identify factors associated with self-reported symptom burden measured using Symptom Screening in Pediatrics Tool (SSPedi) in pediatric patients with cancer. METHODS This was a secondary analysis of a cluster randomized trial enrolling pediatric patients newly diagnosed with cancer. Twenty sites were randomized to routine symptom screening versus usual care. Intervention included thrice-weekly symptom screening with SSPedi, delivery of severely bothersome scores to health care teams, and implementation of locally adapted symptom management care pathways. Primary outcome was total SSPedi scores, 0 (no bothersome symptoms) to 60 (worst bothersome symptoms), obtained at baseline, week four, and week eight in 430 patients (n = 217 intervention and n = 213 usual care). We created a mixed linear regression model evaluating design (including time point), patient/guardian, and site characteristics for their associations with symptom burden after controlling for treatment assignment. RESULTS SSPedi scores were significantly lower at weeks 4 and 8 compared with baseline ( P < .0001 overall), and at intervention versus control sites ( P < .0001). In the full model, males (estimate, –3.3 [95% CI, –4.6 to –2.0]; P < .0001) and sites with higher physician staffing ratios (each physician full-time equivalent per 100 new diagnoses estimate –0.20 [95% CI, –0.5 to 0.0]; P = .024) had significantly lower total SSPedi scores. CONCLUSION Total symptom burden was reduced by time, intervention (symptom screening and care pathways), and greater physician staffing ratio. Females had higher symptom burden. These data may inform programmatic implementation of routine symptom screening in pediatric patients with cancer.

Year:

2025

Cytomolecular features critical for risk-stratified treatment determination in pediatric acute myeloid leukemia (AML) were expanded in Children’s Oncology Group (COG) Phase III trial AAML1831 based on previous trials. It remains unknown whether the cytomolecular risk profiles are generalizable to the real-world. We addressed this knowledge gap using a nationally representative real-world cohort of 913 pediatric AML patients. Distributions of cytomolecular risk profiles and individual markers were comparable for trial-enrolled and non-enrolled patients, as well as across social drivers of trial enrollment (race/ethnicity, language, insurance, acuity). Compared to patients with only favorable cytomolecular markers (4-year overall survival [OS] = 89.48%; 95% CI = 84.46% to 92.95%), patients with both favorable and unfavorable (hazards ratio [HR] = 2.49, 95% CI = 1.18 to 5.23), neutral (HR = 4.33, 95% CI = 2.75 to 6.82), and only unfavorable (HR = 5.80, 95% CI = 3.70 to 9.11) markers all had increased hazards of death. Cytomolecular risk informed by trial data appears to be generalizable to the real-world setting in pediatric AML.

Year:

2025

Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m 2 and gemcitabine 1,000 mg/m 2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (27)

Eneida Nemecek

Professor

Oregon Health & Science University

UNITED STATES
View details

Eric Sandler

Department Chair

Nemours Children's Health System

UNITED STATES
View details

Christine A Pratilas

Vice Chair for Pediatric Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

David Loeb

Professor

Albert Einstein College of Medicine

UNITED STATES
View details

Javier Oesterheld

Clinical (Full) Professor

Wake Forest University

UNITED STATES
View details

Yimei Li

University of Pennsylvania

UNITED STATES
View details

Masanori Hayashi

Assistant Professor

University of Colorado Boulder

UNITED STATES
View details

Ramamoorthy Nagasubramanian

Stanford University

UNITED STATES
View details

Maria Gramatges

Baylor College of Medicine

UNITED STATES
View details

Leo Mascarenhas

Division Chief and Director, Pediatric Hematology-Oncology, Guerin Children's; Director, Sarcoma Program, Cedars-Sinai Cancer

Cedars-Sinai Medical Center

UNITED STATES
View details

Catherine Aftandilian

Stanford University School of Medicine

UNITED STATES
View details

Gary Hettinger

Assistant Professor

NYU Langone Health

UNITED STATES
View details

Jun Yin

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jeffrey Huo

Clinical Assistant Professor

Wake Forest School of Medicine

UNITED STATES
View details

Melissa P. Beauchemin

Assistant Professor of Nursing

Columbia University Irving Medical Center

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Scott Bradfield

Interim Division Chief

Nemours Children's Health System

UNITED STATES
View details

Jeffrey Davis

Clinical Associate Professor

The University of British Columbia

CANADA
View details

Matteo Trucco

Associate Professor

Cleveland Clinic

UNITED STATES
View details

Alix Seif

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Scott Borinstein

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Sung Choi

MD / Associate Professor

University of Michigan Hospital

UNITED STATES
View details

Blachy Dávila Saldaña

Associate Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Lars Wagner

division of pediatric hematology‐oncology duke university medical center durham north carolina usa

UNITED STATES
View details

Andrew Harris

Associate Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Nataliya Buxbaum

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Christopher Dvorak

University of California, San Francisco

UNITED STATES
View details